St. Jude Medical announced the FDA has cleared a new cardiac mapping system and mapping catheter for use during catheter ablation for treatment of arrhythmias.
The new cardiac mapping system (EnSite Precision) provides physicians with detailed anatomical models and maps, enabling more efficient treatment of complex arrhythmias, including atrial fibrillation and ventricular tachycardia, the company stated in a press release.
Also cleared was a sensor-enabled circular mapping catheter (Advisor FL), according to the release.
John D. Day
The mapping system includes a module (EnSite AutoMap Module) enabling quick identification of the source of the arrhythmia and a feature (TurboMap) which allows physicians to build a map of the heart 10 times faster than with existing systems, according to the release.
The new products enable catheter navigation with minimal fluoroscopy, reducing risk for adverse events associated with excessive radiation exposure, the company stated in the release.
Disclosure: Day reports no relevant financial disclosures.